Vandria

Vandria is a clinical-stage Swiss biopharmaceutical company developing small molecules that induce mitophagy, the selective clearance of damaged mitochondria, to restore cellular energy production and reduce chronic inflammation in age-related disease. Led by CEO Dr. Klaus Dugi, the company raised a $32M Series A and advanced its lead candidate VNA-318 into a first-in-human Phase 1 trial, with the program aimed at indications including mild cognitive impairment, Alzheimer's, Parkinson's and major depressive disorder, and described as having both immediate cognitive benefits and long-term disease-modifying potential. Vandria has signaled plans for parallel Phase 2a studies in patient populations, positioning mitochondrial quality control as a lever against the biology of aging.